Invesco
ADCT icon

Invesco’s ADC Therapeutics ADCT Stock Holding History

Invesco’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.7K Buy
55,762
+14,132
+34% +$41.2K ﹤0.01% 3785
2026
Q1 		$156K Buy
41,630
+1,419
+4% +$5.59K ﹤0.01% 3552
2025
Q4 		$142K Buy
40,211
+1,422
+4% +$5.77K ﹤0.01% 3598
2025
Q3 		$155K Sell
38,789
-93,429
-71% -$295K ﹤0.01% 3615
2025
Q2 		$354K Sell
132,218
-486
-0.4% -$1.02K ﹤0.01% 3307
2025
Q1 		$187K Buy
132,704
+98,335
+286% +$167K ﹤0.01% 3525
2024
Q4 		$68.4K Buy
34,369
+1,700
+5% +$4.45K ﹤0.01% 3667
2024
Q3 		$103K Sell
32,669
-290
-0.9% -$915 ﹤0.01% 3617
2024
Q2 		$104K Buy
+32,959
New +$131K ﹤0.01% 3745
2022
Q1 		– Sell
-242,643
Closed -$4.9M – 4000
2021
Q4 		$4.9M Buy
242,643
+19,045
+9% +$459K ﹤0.01% 2420
2021
Q3 		$6.07M Sell
223,598
-2,110
-0.9% -$54K ﹤0.01% 2282
2021
Q2 		$5.5M Sell
225,708
-8,146
-3% -$189K ﹤0.01% 2387
2021
Q1 		$5.71M Buy
233,854
+3,692
+2% +$107K ﹤0.01% 2313
2020
Q4 		$7.37M Buy
230,162
+70,386
+44% +$2.31M ﹤0.01% 1966
2020
Q3 		$5.27M Buy
+159,776
New +$6.92M ﹤0.01% 1983

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco's ADCT Position: Q2 2026 in Review

Invesco increased its ADC Therapeutics (ADCT) stake by 34% in Q2 2026, buying an estimated $41.2K and bringing the position to 55,762 shares worth $59.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3785.

Invesco first reported a position in ADCT in Q3 2020 and has held it in 15 quarters since. The position peaked at $7.37M in Q4 2020. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Invesco held 55,762 shares of ADC Therapeutics worth $59.7K as of Q2 2026.
  • Invesco bought 14,132 ADC Therapeutics shares in Q2 2026, an estimated $41.2K.
  • ADC Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3785 holding.
  • Invesco first reported a position in ADC Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • Invesco's ADC Therapeutics position peaked at $7.37M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.